ifosfamide has been researched along with HIV in 1 studies
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Reid, EG | 1 |
Looney, D | 1 |
Maldarelli, F | 1 |
Noy, A | 1 |
Henry, D | 1 |
Aboulafia, D | 1 |
Ramos, JC | 1 |
Sparano, J | 1 |
Ambinder, RF | 1 |
Lee, J | 1 |
Cesarman, E | 1 |
Yahyaei, S | 1 |
Mitsuyasu, R | 1 |
Wachsman, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma[NCT00598169] | Phase 1 | 23 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for ifosfamide and HIV
Article | Year |
---|---|
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; APOBEC-3G Deaminase; Bortezomib; Carbop | 2018 |